Skip to Content


Recent technological advances have made it possible to measure microbial content within body sites without the need for culturing the agent. Through several metabolic, detoxification, and immunologic pathways, the human microbiota is essential for human health and hypothesized to be an important determinant of various diseases, including cancer. Most work to date in this area has been descriptive, laboratory-based, and limited by small sample sizes. Epidemiological studies of the relationship between microbial diversity and cancer risk are just now being explored. 

To prepare for such studies, DCEG investigators have been accumulating expertise and have embarked on a series of pilot studies to develop tools and to test particular hypotheses that will ultimately provide understanding of how cancer risk is affected by perturbations of the microbiota and its functions. These include:

  1. an ongoing study of 150 healthy individuals to evaluate microbial patterns at multiple body sites over time and across individuals, 
  2. a twin study of Hodgkin lymphoma designed to compare 16S rRNA sequence diversity between twins that were discordant for Hodgkin lymphoma, and 
  3. a methods study to evaluate the potential utility of the widely used fecal occult blood test device for biobanking designed to allow for longitudinal epidemiological studies of the microbiota and cancer.

For more information, contact James Goedert or Mahboobeh Safaeian.

Infections and Immunoepidemiology Branch – Research Areas